In a preliminary report by Smith, Espir, Whitty, and Russell (1957) it was suggested that the intrathecal administration of purified protein derivative of tuberculin (P.P.D.) might be beneficial to patients with multiple sclerosis. It was also observed that apart from the immediate reaction no patient deteriorated who had experienced a definite response. These workers were unable to find evidence of any new lesions developing in patients who had been treated in this way although fluctuations were found in pre-existing symptoms. Attention was drawn to well-marked remissions and the change was noted from an expected fluctuating downhill course to moderate improvement. They, therefore, presented their preliminary report in the hope that others might expand this work.
PLAN OF THE TRIAL
In accordance with these suggestions we planned to administer P.P.D. intrathecally to a number of patients with multiple sclerosis and to observe their reactions and the subsequent course of the illness. Since the best regime for injecting P.P.D. has not yet been found, it was proposed to try a number of methods and to compare results. Thirty-six patients with multiple sclerosis were selected from the admissions to the Neurological Unit; all except one had had several episodes and showed clinical evidence of recent activity. The majority were ambulant. Patients with severe bladder disturbances, or permanently bed-ridden, or having marked mental changes, were excluded. Similarly no patient suffering from retrobulbar neuritis alone was selected. The details of the group selected are summarized in Table I . Their ages were between 18 and 56 years. Eleven were men and 25 were women. The duration of the illness varied between 22 years and three months, but 28 patients had a history of more than three years. Those who were deteriorating or had recently had fresh relapses were considered to be the 'Member of the external scientific staff, Medical Research Council. most suitable for the treatment, as being in greatest need of an active therapeutic regime.
All were examined on admission and their physical capacity assessed. Routine investigations included a chest radiograph, full blood count, sedimentation rate, and urine examination. In addition, each patient was Mantoux tested using solutions of 1 in 10,000, 1 in 1,000, 1 in 100, and 1 in 10 P.P.D., and, if indicated, depot testing with tuberculin intradermally was also performed (Pepys, Bruce, and James, 1958) . This was done on our behalf by Dr. Geraint James. All except two cases were Mantoux positive but these two were subsequently vaccinated with B.C.G. to ensure a positive tuberculin reaction. To mitigate some of the severe reactions which occurred, patients were treated with antipyretics, urinary antiseptics, or catheterization as required.
To modify the deleterious effects seen in some cases adrenocorticotrophic hormone (A.C.T.H.) was given intramuscularly. A small number of patients who had extreme skin sensitivity to P.P.D. were desensitized by means of increasing doses of intramuscular purified protein derivative.
For the intrathecal therapy, the standard dilution of P.P.D. solution prepared by Messrs. Allen and Hanbury from P.P.D. made at the Ministry of Agriculture and Fisheries, Weybridge, was employed. This was dissolved in borate buffer and contained 7-5 micrograms of P.P.D. per millilitre and it was used in strengths of 1 in 100, 1 in 10, and undiluted. The amount given initially was determined by the extent of the skin sensitivity in the Mantoux test. Before administering the P.P.D. a small amount of cerebrospinal fluid was taken off at lumbar puncture and this puncture was repeated, usually after 48 hours but in some cases also at 24 hours. Four patients had one injection of intrathecal P.P.D., 14 patients had two injections, 15 patients had three injections, two patients had four injections, and one patient had six injections (Table I) .
The follow-up was carried out by seeing the patients at regular intervals but six were unable to attend for this purpose and information about their 79 condition has been obtained from their medical developed acute reactions which took the form of practitioners. As a part of the follow-up many severe headache, drowsiness, pyrexia, nausea, pains patients were re-admitted to have their condition in the limbs, neck stiffness, photophobia, and other reassessed. In judging the course of the illness, the signs of meningeal irritation. Sometimes these opinions of their relatives were obtained whenever symptoms began as late as 36 hours after the intrapossible. thecal injection. Many showed a transient exacerAt the beginning of the trial patients were informed bation of the physical signs which gradually subthat this method of treatment was an experimental sided. Bladder complications were so common as to undertaking but that it had been claimed to be be regarded as part of the reaction, and usually took beneficial.
the form of acute retention. Carbachol was given for this but was often unsuccessful so that catheteri- 
RESULTS OF FOLLOW-UP
The results are shown in Table I . The appearance of new symptoms and signs after the initial reaction had subsided is described in this table as a relapse, as is the sudden marked deterioration compared with the previous state. Transient disturbances were not taken into account in this assessment. Gradual deterioration leading to a change in the patient's functional capacity is recorded as a worsening of the condition. Table I shows the state of the patients at one year and also the last known condition.1 Thirtyfour months after the beginning of this investigation the position was as follows:-Out of the 36 patients five were improved, one was unchanged, four were slightly worse, 19 were worse, five much worse, one could not be traced, and one had died. The last was a man who had been grossly restricted in physical activity leading a wheelchair existence at the beginning of the treatment. He died within a few months of pyelonephritis. ' Fuller clinical details will be sent to those interested, on request.
Time after First
Injection LATE COMPLICATIONS Two patients developed severe nocturnal pain in the trunk at 10 and 11 months respectively. They both described pain waking them in the early hours of the morning, intermittent at first and then becoming more continuous. In one a segmental level of blunting to pin prick was found. Both were investigated for possible visceral causes for the pain but none were found. It is possible that spinal arachnoiditis due to the injection of P.P.D. was responsible for these symptoms.
RELAPSE RATES During the first year after the injection of P.P.D. 30 relapses were noted and these occurred in 24 out of the 36 patients. In the first six weeks after therapy three relapses occurred. Eight relapses took place in the second six weeks, five relapses from 12 to 26 weeks, and 14 relapses from six months to one year.
In Tables HA and UB these rates have been analysed. Table IhA shows the number of first relapses in the above periods. Table UB shows the incidence of all the relapses during the same intervals. As can be seen, the period from seven to 12 weeks inclusive had the highest incidence of first relapses and also of the total number of relapses. In Table JIB the patient who could not be traced has been omitted. (1957) we observed two patients with respiratory failure. These had previously shown signs of brain-stem damage, and it seems reasonable to suppose that an extension of a preexisting lesion in this region was responsible for the failure of respiration. In the natural course of multiple sclerosis respiratory complications have been observed. Urinary disturbances were very common. They took the form of increased frequency, urgency or precipitancy of micturition, or incontinence. Retention with or without overflow occurred in many patients. This was most serious as it led to severe infection. Such disturbances of micturition were very persistent, lasting many months and leading to marked physical deterioration and loss of morale. The pathological changes responsible for the sphincter disorders are not known, but one possibility which should be considered is that the P.P.D. becomes absorbed or fixed near the site of injection on the lumbosacral roots and conus medullaris and that the subsequent meningeal reaction which is of an immunological nature, tends to be very severe at these sites. An alternative possibility is that preexisting lesions of the spinal cord flared up. There was evidence that fresh spinal lesions might occur, as one patient developed a Brown-Sequard syndrome from which she took many months to recover. Previously she had not had any clinical evidence of a lesion at the affected level of the spinal cord.
A rising level of protein after intrathecal P.P.D. has been described but one patient in this series developed manometric evidence of a complete spinal block which subsequently remitted. It is considered that if the protein level in the cerebrospinal fluid becomes greatly raised the possibility of a spinal block should be suspected. It is also of interest that in two patients symptoms suggestive of spinal arachnoiditis appeared at a late stage. The details of 8 the changes found in the cerebrospinal fluid with particular reference to the protein fractions will be discussed in another paper but Table I shows the highest level of protein which developed and also the findings preceding treatment.
If the relapse rate is compared with that noted by McAlpine, Compston, and Lumsden (1955) Our findings are very different from those noted by Smith et al. The severe initial complications, the high relapse rate, and the large percentage of patients whose condition became worse has been a striking feature in this series. The source of P.P.D. was the same in both series (Weybridge) but it is conceivable that when dealing with such complex biological material as P.P.D. there may be variations in its composition. The dose of P.P.D. given to our patients on the whole seems to be smaller than that given by the Oxford workers. We have considered the possibility that the A.C.T.H. which was given to ameliorate the acute reaction could be responsible for the differences in the findings but our own experience of the use of A.C.T.H. would not support this view. Nor is this borne out by the work of Alexander, Berkeley, and Alexander (1958) . The worsening of the clinical status of many patients was a gradual deterioration quite independent of obvious relapses. It is probable that theurinaryinfectionsmay have contributed towards this.
A preliminary report by Miller, Newell, Ridley, and Schapira (1961) at the meeting of the Association of British Neurologists of a controlled series of patients treated with intrathecal P.P.D. did not indicate any differences in patients treated in this way and those who received intrathecal saline. Kelly and Jellinek (1961) reported similar findings. Marshall and O'Grady (1959) injected P.P.D. intrathecally into 17 patients with multiple sclerosis but did not consider that they had sufficient data to assess the effects of the treatment. They reported loss of sphincter control persisting for several weeks.
A recent publication by Smith, Hughes, and Hunter (1961) states that there was diminution of the relapse rate in patients with multiple sclerosis treated in this way if they developed a protein exceeding 550 mg. in cerebrospinal fluid with a low cell count. Table I does not indicate that patients who develop a high protein level fared any better than the others. Owing to different times at which lumbar puncture was performed it is not possible to compare the results in relation to the cellular reactions.
Purified protein derivative is made (Paterson, 1957) by treating the steamed culture filtrate of M. tuberculosis grown on a synthetic medium with trichloracetic acid. The precipitated protein is washed with diluted trichloracetic acid, redissolved and then clarified by filtration or by Sharples centrifugation. Its stability is affected by storage conditions and it is unstable in high dilution. Magnus, Guld, Waaler, and Magnusson (1956) drew attention to loss of its potency by absorption on to the glass ampoules.
The known components of P.P.D. include nucleic acid, polysaccharide, lipopolysaccharide, lipid, and a number of proteins. Some of these substances are present in small amounts as impurities. Seibert (1950) noted the partial degradation of P.P.D. by the heating process used in its preparation, and in unheated P.P.D. material which she prepared she found three separate proteins of different potencies, one of which was more active in higher dilutions. Later Seibert, Soto Figueroa, and Dufour reported (1955) that variable amounts of these proteins were produced in culture filtrates from time to time regardless of the strain (of the organism), the time of growth, medium used, or method of isolation, and that to obtain protein fractions with reproducible and constant compositions special methods of preparation would be necessary.
It might appear that these conclusions would be equally Burtin, Kourilsky, Uriel, and Ternynck (1959) and Burtin, Uriel, and Ternynck (1959) reported the presence of both polysaccharide and lipopolysaccharide derivatives in culture filtrates of tubercle bacilli. In 1958 Colover showed that purified tubercle bacillus lipopolysaccharide had encephalitogenic properties in guinea-pigs, and it is therefore conceivable that P.P.D. may contain small quantities of such encephalitogenic substances. The amounts, however, which might be injected in humans according to the dose scale shown in Table 1 would be much less than those which were employed experimentally in guinea-pigs. It is considered that in regard to P.P.D. treatment of multiple sclerosis there is a state of uncertainty concerning the chemical composition of this material. Theresults ofthis therapy will be variable until purified preparations of P.P.D. of known biochemical composition and immunological behaviour are obtainable and it is understandable that with the material as at present available different observers may obtain different results and that these will be unpredictable. If it is confirmed that the P.P.D. complex as made at present contains encephalitogenic substances then it is clearly undesirable that it should be administered intrathecally.
SUMMARY
Thirty-six patients with multiple sclerosis were treated with intrathecal P.P.D. and their condition observed over a period varying from 16 to 34 months.
No evidence was found of any favourable effects, most deteriorated, and there was a high relapse rate.
The highest relapse rate was noted between the sixth and twelfth week after P.P.D. injection. Statistical analysis of the results suggested that this high relapse rate could have been related to the treatment. If this were so, then it could be evidence that some naturally occurring relapses in multiple sclerosis might similarly be caused by an immuno-
